ChinaBio® Partnering Forum is part of the Informa Connect Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Dr Carl Firth is Founder and Chief Executive Officer of ASLAN Pharmaceuticals. Prior to founding ASLAN, Carl was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies and advising on M&A transactions. Prior to joining the banking industry, Carl worked for AstraZeneca across various commercial and R&D roles, including Regional Business Development Director, Asia Pacific, and Director of New Product Development, China.
Carl is currently a member of Singapore’s Health and Biomedical Sciences International Advisory Council. He is an independent commercialization director arm of Exploit Technologies, a Singapore’s Agency for Science, Technology and Research (A*STAR), which supports A*STAR in its efforts to transform the economy by driving innovation and commercialising its research outcomes.
Previously, Carl was an independent director of Hong Kong listed Uni-Bio Sciences, a leading Chinese biopharmaceutical company engaged in the research, development, production and commercialization of
Biopharmaceuticals for the Chinese healthcare market, where he served in such capacity from April 2014 to November 2017.
Carl is an Adjunct Professor at Duke-NUS Medical School. He has a PhD in Molecular Biology from Cambridge University (Trinity College), an Executive MBA from London Business School; and a BA in
Molecular Biology from Cambridge University.